Tags

Type your tag names separated by a space and hit enter

Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers.
J Travel Med. 2018 01 01; 25(1)JT

Abstract

Background

Few studies have assessed the duration of humoral immunity following yellow fever (YF) vaccination in a non-endemic population. We evaluated seropositivity among US resident travellers based on time post-vaccination.

Methods

We identified serum samples from US travellers with YF virus-specific plaque reduction neutralization testing (PRNT) performed at CDC from 1988 to 2016. Analyses were conducted to assess the effect of time since vaccination on neutralizing antibody titer counts.

Results

Among 234 travellers who had neutralizing antibody testing performed on a specimen obtained ≥1 month after vaccination, 13 received multiple YF vaccinations and 221 had one dose of YF vaccine reported. All 13 who received more than one dose of YF vaccine had a positive PRNT regardless of the amount time since most recent vaccination. Among the 221 travellers with one reported dose of YF vaccine, 155 (70%) were vaccinated within 10 years (range 1 month-9 years) and 66 (30%) were vaccinated ≥10 years (range 10-53 years) prior to serum collection. Among the 155 individuals vaccinated, <10 years prior to serum collection, 146 (94%) had a positive PRNT compared with 82% (54/66) of individuals vaccinated ≥10 years prior to serum collection (P = 0.01). Post-vaccination PRNT titers showed a time-dependent decrease. Individuals with immunocompromising conditions were less likely to have a positive PRNT (77%) compared with those who were not immunocompromised (92%; P = 0.04).

Conclusion

Although the percentage of vaccinees with a positive PRNT and antibody titers decreased over time, a single dose of YF vaccine provided long-lasting protection in the majority of US travellers. A booster dose could be considered for certain travellers who are planning travel to a high risk area based on immune competence and time since vaccination.

Authors+Show Affiliations

Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, CO, USA.Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, CO, USA.Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, CO, USA.Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, CO, USA.Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, CO, USA.Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, CO, USA.Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, CO, USA.Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, CO, USA.Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, CO, USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

30346562

Citation

Lindsey, Nicole P., et al. "Persistence of Yellow Fever Virus-specific Neutralizing Antibodies After Vaccination Among US Travellers." Journal of Travel Medicine, vol. 25, no. 1, 2018.
Lindsey NP, Horiuchi KA, Fulton C, et al. Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers. J Travel Med. 2018;25(1).
Lindsey, N. P., Horiuchi, K. A., Fulton, C., Panella, A. J., Kosoy, O. I., Velez, J. O., Krow-Lucal, E. R., Fischer, M., & Staples, J. E. (2018). Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers. Journal of Travel Medicine, 25(1). https://doi.org/10.1093/jtm/tay108
Lindsey NP, et al. Persistence of Yellow Fever Virus-specific Neutralizing Antibodies After Vaccination Among US Travellers. J Travel Med. 2018 01 1;25(1) PubMed PMID: 30346562.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers. AU - Lindsey,Nicole P, AU - Horiuchi,Kalanthe A, AU - Fulton,Corey, AU - Panella,Amanda J, AU - Kosoy,Olga I, AU - Velez,Jason O, AU - Krow-Lucal,Elizabeth R, AU - Fischer,Marc, AU - Staples,J Erin, PY - 2018/09/10/received PY - 2018/10/18/accepted PY - 2018/10/23/pubmed PY - 2019/7/16/medline PY - 2018/10/23/entrez JF - Journal of travel medicine JO - J Travel Med VL - 25 IS - 1 N2 - Background: Few studies have assessed the duration of humoral immunity following yellow fever (YF) vaccination in a non-endemic population. We evaluated seropositivity among US resident travellers based on time post-vaccination. Methods: We identified serum samples from US travellers with YF virus-specific plaque reduction neutralization testing (PRNT) performed at CDC from 1988 to 2016. Analyses were conducted to assess the effect of time since vaccination on neutralizing antibody titer counts. Results: Among 234 travellers who had neutralizing antibody testing performed on a specimen obtained ≥1 month after vaccination, 13 received multiple YF vaccinations and 221 had one dose of YF vaccine reported. All 13 who received more than one dose of YF vaccine had a positive PRNT regardless of the amount time since most recent vaccination. Among the 221 travellers with one reported dose of YF vaccine, 155 (70%) were vaccinated within 10 years (range 1 month-9 years) and 66 (30%) were vaccinated ≥10 years (range 10-53 years) prior to serum collection. Among the 155 individuals vaccinated, <10 years prior to serum collection, 146 (94%) had a positive PRNT compared with 82% (54/66) of individuals vaccinated ≥10 years prior to serum collection (P = 0.01). Post-vaccination PRNT titers showed a time-dependent decrease. Individuals with immunocompromising conditions were less likely to have a positive PRNT (77%) compared with those who were not immunocompromised (92%; P = 0.04). Conclusion: Although the percentage of vaccinees with a positive PRNT and antibody titers decreased over time, a single dose of YF vaccine provided long-lasting protection in the majority of US travellers. A booster dose could be considered for certain travellers who are planning travel to a high risk area based on immune competence and time since vaccination. SN - 1708-8305 UR - https://www.unboundmedicine.com/medline/citation/30346562/Persistence_of_yellow_fever_virus_specific_neutralizing_antibodies_after_vaccination_among_US_travellers_ L2 - https://academic.oup.com/jtm/article-lookup/doi/10.1093/jtm/tay108 DB - PRIME DP - Unbound Medicine ER -